YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Halozyme Therapeutics HALO announced that a Dutch patent court has issued a ruling in its favor in a patent dispute with Merck MRK over Keytruda's subcutaneous (SC) formulation. The court found that Merck's Keytruda SC infringes one of Hal…
Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's par…
In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affe…
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets. Continue Reading
Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets. Before you buy NVIDIA: our AI model's stock p…
Halozyme Therapeutics HALO announced that it has expanded the global collaboration and license agreement with argenx ARGX to develop and commercialize its ENHANZE technology with two additional exclusive targets. The expanded collaboration…
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents…
Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expan…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:H…
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceuti…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) an…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q2. Today, we are lookin…
An updated edition of the August 7, 2026 article. Women are taking on a growing role in corporate leadership, with more female executives guiding publicly traded companies across diverse industries. Their influence extends well beyond repr…
If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, you can try the growth at a reasonable price or GARP strategy. The strategy helps investors gain exposure to undervalued stocks with i…
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well. The fear of…
Halozyme Therapeutics (HALO) shares ended the last trading session 3.3% higher at $115.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.6% g…
1 Cash-Producing Stock to Target This Week and 2 We Question Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to…
On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $1…
Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di…
Looking for broad exposure to the Mid Cap Growth segment of the US equity market? You should consider the Invesco S&P MidCap 400 Pure Growth ETF (RFG), a passively managed exchange traded fund launched on March 1, 2006. The fund is sponsor…
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial purchasers to buy another $150 million.…
* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) on Thursday announced the pricing of $1.3B aggregate principal amount of 1.50% convertible senior notes due 2033. * The offering size was increased from the previously a…
SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Con…
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal…
Halozyme Therapeutics (HALO) heads into a busy investor calendar, with management scheduled to speak at three major healthcare and investment conferences in early and mid September 2026, putting the stock back under the spotlight. Despite…
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nat…
For Immediate Release Chicago, IL – September 15, 2026 – Stocks in this week's article are Halozyme Therapeutics HALO, Avnet, Inc. AVT, BILL Holdings, Inc. BILL and Venture Global, Inc. VG. 4 Best PEG Value Stocks to Buy Now for Strong Gro…
The U.S. economy is entering a more challenging environment as renewed Middle East tensions push oil prices above $100 a barrel, adding to inflationary pressures. Annual CPI inflation accelerated to 3.4% in August, well above the Federal R…
At a time when volatility strikes every second day, investors often rely on value investing rather than other options like growth or momentum. As soon as other investors start selling their stocks at a cheaper rate in times of market uncer…
With the stock market on shaky ground, investors should be adjusting their portfolio management and taking some profits. For about a half-dozen components of Investor's Business Daily's IBD 50 list, the decision on when to sell stocks is a…
HALO offers novel oncology treatments targeting tumors and a platform for subcutaneous drug delivery. Its second-quarter fiscal 2026 earnings report showed revenue of $481 million (a record 48% year-over-year rise), non-GAAP diluted per-sh…